Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.290
+0.010 (0.78%)
At close: May 13, 2025, 4:00 PM
1.250
-0.040 (-3.10%)
Pre-market: May 14, 2025, 6:17 AM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,252,833
Market Cap
2.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLMD News
- 8 days ago - Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PRNewsWire
- 15 days ago - Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PRNewsWire
- 26 days ago - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PRNewsWire
- 4 weeks ago - Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 4 weeks ago - Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 5 weeks ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - PRNewsWire
- 7 weeks ago - Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PRNewsWire
- 8 months ago - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PRNewsWire